Background: Pioglitazone may be beneficial in the treatment of psoriasis. However, based on the effectiveness and safety considerations, it has not been widely used. To fully evaluate the strength of evidence supporting psoriasis treatment with pioglitazone, we conducted a meta-analysis of existing published studies. Methods: PubMed, Ovid, Cochrane Library, Google Scholar, and Web of Science databases were systematically searched before February 2019. Randomized controlled trials (RCTs) of pioglitazone administration compared with placebo, administered to patients with psoriasis for at least 10 weeks, and published in English were included. Quality of the included RCTs was identified by the modified Jadad scale. The quality of evidence for each outcome was evaluated using the GRADEpro Guideline Development Tool online software. Primary outcomes were proportion of patients showing psoriasis area and severity index (PASI) score improvement (>75%) and the mean percent change in PASI score from baseline to the end of treatment. Dichotomous data were analyzed using odds ratios (ORs) corresponding to the 95% confidence interval (CI), whereas continuous variables, expressed as mean and standard deviation, were analyzed using the mean differences (MD) with the 95% CI. Results: Six RCTs were analyzed. Meta-analysis showed that pioglitazone reduced the PASI scores in patients with psoriasis compared with the control group when administered at 30 mg per day (P < 0.001, MD = –3.82, 95% CI = –5.70, –1.93) and at 15 mg per day (P = 0.04, MD = –3.53, 95% CI = –6.86, –0.20). The PASI-75 of the pioglitazone group was significantly higher than that of the control group at 30 mg per day (P < 0.001, OR = 8.30, 95% CI = 3.99, 17.27) and at 15 mg per day (P = 0.03, OR = 2.96, 95% CI = 1.08, 8.06). No statistically significant differences in total adverse events were observed between the groups. There were no significant differences in common adverse reactions such as weight gain and elevated liver enzymes between the two pioglitazone groups. Conclusions: Use of pioglitazone in the current treatment of psoriasis is beneficial. The therapeutic effect of the daily 30 mg dose may be greater than that of the 15 mg dose per day with no significant change in the frequency of adverse reactions.
Background : Human papillomavirus (HPV) is associated with cervical cancer and genital condyloma, which is mainly transmitted through sexual contact.Cervical HPV infection in females and genital HPV infection in males can induce epithelial proliferation on both mucosal and cutaneous surfaces. HPV is divided into high-risk (HR) and low-risk (LR) types according to their oncogenic potential. The HR geneotypes are considered as etiological factors for invasive cervical cancer in females, and the LR geneotypes are correlated with hyperplastic lesions, including external genital warts, condyloma acuminata, and so on. The aim of this study was to investigate the prevalence of HPV infection and geneotype distribution among individuals in Xinjiang Province.Methods A total of 1094 patients the etiology and species with characteristic of cervical and genital warty surface which mainly come from CA in dermatology and STD outpatient service of People's Hospital of Xinjiang Uygur Autonomous Region.Using a method of real-time uorescence quantitative PCR for the detection of human papilloma virus HPV 23 typing. ResultsThe prevalence of HPV infection was 67.46%, the most common LR-HPV subtypes were HPV-6 (16.27%), HPV-11 (4.57%), HPV-42(1.19%) and , and HR-HPV subtypes were HPV-16 (1.65%) and HPV-58(0.91%). The prevalence of HPV infection with single subtype and multiple subtypes was 32.91% and 34.55%, respectively. Among the females infected with a single HPV subtype, 26.11%were infected with a HR-HPV subtype. Among the females infected with multiple HPV subtypes, 18.52%were infected with multiple HR-HR HPV subtypes. The prevalence and subtype distribution of HPV infection showedage differences ( P =0.012), and the prevalence peak of HPV infection was observed in females aged 20-29 years (292/404, 72.28%). ConclusionThe prevalence of multiple infection was higher than singleinfection, and the prevalence varied signi cantly with age while had little association with race and gender.
Iron deficiency has been associated with telogen effluvium, but currently, the data regarding their association are conflicting. To derive a more precise estimation of this association, we performed a systematic review and meta-analysis to investigate serum ferritin level, serum iron level, and prevalence of ferritin deficiency in all published studies. Databases including PubMed, Google Scholar, Offshore Vessel Inspection Database, and Cochrane Library, were systematically searched. The association was assessed using standardized mean differences, odds ratios, and 95% confidence intervals. Statistical analysis was performed using Review Manager version 5.4.1. A total of 20 studies were identified. The results showed that in patients with telogen effluvium, including those with acute and chronic telogen effluvium, serum iron and serum ferritin levels were lower than those in the normal population. There was no significant difference in serum ferritin and iron levels between patients with acute and chronic telogen effluvium. In patients with chronic telogen effluvium, the prevalence of ferritin deficiency was higher than that in the general population when ferritin levels were 20 ng/dl and 30 ng/dl as the threshold for the diagnosis of iron deficiency. This meta-analysis revealed that iron deficiency is associated with telogen effluvium and clarified the critical serum ferritin level for defining iron deficiency in patients with telogen effluvium.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.